(NASDAQ: HALO) Halozyme Therapeutics's forecast annual revenue growth rate of 14.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Halozyme Therapeutics's revenue in 2025 is $1,084,306,000.On average, 4 Wall Street analysts forecast HALO's revenue for 2025 to be $154,039,188,205, with the lowest HALO revenue forecast at $150,019,103,080, and the highest HALO revenue forecast at $158,902,104,970. On average, 5 Wall Street analysts forecast HALO's revenue for 2026 to be $176,889,413,666, with the lowest HALO revenue forecast at $150,264,312,870, and the highest HALO revenue forecast at $193,456,970,000.
In 2027, HALO is forecast to generate $197,955,152,605 in revenue, with the lowest revenue forecast at $165,771,675,720 and the highest revenue forecast at $228,156,003,600.